Next-generation CELMoDs (iberdomide, mezagdomide) show promise beyond direct tumor killing. Their ability to reduce or reverse T-cell exhaustion suggests they could be used to 'prime' a patient's immune system, potentially restoring function before or after treatment with a CAR-T or bispecific T-cell engager.
When choosing between BCMA-directed therapies, using CAR-T therapy first may be strategically advantageous. Early evidence suggests continuous T-cell engager (bispecific) therapy may exert more selective pressure, leading to a higher risk of BCMA target loss through mutation or deletion compared to one-time CAR-T infusions.
In less than two decades, the median progression-free survival (PFS) for a standard-risk multiple myeloma patient has dramatically increased from 3-5 years in 2006 to a projected 15-16 years today. This leap is largely attributed to the introduction of quadruplet regimens, particularly those including anti-CD38 antibodies.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.
Within the next 3-5 years, the treatment paradigm for newly diagnosed myeloma will likely shift to upfront CAR-T and bispecific therapies. Experts believe this will enable fixed-duration treatments with curative intent, ultimately diminishing the role of autologous stem cell transplant, particularly in the United States.
The profound success of anti-CD38 antibodies like daratumumab isn't just due to their direct anti-myeloma effect. A key part of their efficacy comes from altering the tumor microenvironment by reducing immunosuppressive T-regulatory cells and expanding anti-tumor T-cell clones, creating a synergistic effect.
The durability of CAR-T responses is prompting a paradigm shift. With a plateau forming on survival curves, where a third of heavily pretreated patients remain relapse-free five years post-infusion, experts are now seriously discussing how to formally define a 'cure' for multiple myeloma.
GPRC5D-targeting bispecifics like talquetamab require a specific learning curve due to their unique 'on-target, off-tumor' side effects. Because the GPRC5D target is also present on skin and taste bud tissues, patients can experience significant dysgeusia, skin changes, and nail toxicities that require active management.
